<i>SRD5A2</i> hypermethylation of specific CpG sites (CpG # -39 to -2) in the promoter region was correlated with OS and PFS of CRPC patients in the Local CRPC cohort.

Patients were divided into a hypermethylation group and a hypomethylation group with a cutoff value of 37.9%, based on the average methylation level of specific CpG sites (CpG# -39 to -2). (A) Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on CpG methylation sites (CpG # -39 to -2). (B) The difference of OS between the hypermethylation group and hypomethylation group. (C) The correlation between methylation level and OS. (D) The difference of PFS between the two groups. (E) The correlation between SRD5A2 methylation and PFS.</p

Hypermethylation of <i>SRD5A2</i> in the whole promoter region (CpG # -72 to 65) was correlated with OS and PFS of CRPC patients in the Local CRPC cohort.

Patients were divided into a hypermethylation group and a hypomethylation group with a cutoff value of 46.5%, based on the average methylation level of all methylation sites. (A) Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on all CpG methylation sites. (B) The difference of OS between the hypermethylation group and hypomethylation group. (C) The correlation between methylation level and OS. (D & E) Patients were divided into a hypermethylation group and a hypomethylation group with a cutoff value of 42%, based on the average methylation level of all methylation sites. (D) The difference of PFS between the two groups. (E) The correlation between methylation level and PFS.</p

Protein expression of SRD5A2 was negatively correlated with <i>SRD5A2</i> promoter methylation.

(A to C) IHC with anti-SRD5A2 antibody. (A) Representative pictures of IHC. (B) The immunoreactive score was correlated with SRD5A2 promoter methylation on CpG# -72 to 65. (C) The immunoreactive score was correlated with SRD5A2 promoter methylation on CpG# -39 to -2. (D to F) TCGA data analysis. (D) SRD5A2 promoter methylation in primary PCa. (E) SRD5A2 expression in primary PCa. (F) The association between SRD5A2 promoter methylation and SRD5A2 expression. Blue rows represented the methylation levels of SRD5A2 promoter region, yellow rows represented SRD5A2 expression, and each column represented one sample.</p

Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Tria

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Tria

Supplementary Appendix from Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors

This file contains additional details on the supplementary methods, plus supplementary tables and legends.</p

<i>SRD5A2</i> hypermethylation of specific CpG sites (CpG # -39 to 65) in the promoter region was correlated with OS and PFS of CRPC patients.

Survival analysis was done based on clustering analysis of methylation site modules (CpG#-39 to 65 average methylation level). (A to D) In the Local CRPC cohort, patients were divided into a hypermethylation group and a hypomethylation group with a cutoff value of 23.3%, based on the average methylation level of specific CpG sites (CpG# -39 to 65). (A) The difference of OS between the two groups. (B) The correlation between SRD5A2 promoter methylation level and OS. (C) The difference of PFS between the two groups. (D) The correlation between methylation level and PFS. (E to H) In the Met CRPC cohort, patients were divided into a hypermethylation group and a hypomethylation group with a cutoff value of 28.0%, based on the average methylation level of specific CpG sites (CpG# -39 to 65). (E) The difference of OS between the two groups. (F) The correlation between methylation level and OS. (G) The difference of PFS between the two groups. (H) The correlation between methylation level and PFS.</p

Hypermethylation of the <i>SRD5A2</i> promoter region in CRPC.

(A) The ratio of SRD5A2 promoter methylation on individual CpG sites in the promoter region in CRPC and benign prostatic tissues in the Local CRPC cohort. (B) The ratio of SRD5A2 DNA promoter methylation on individual CpG sites in CRPC and benign prostatic tissues in the Met CRPC cohort. (C) Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on all CpG methylation sites in the Local CRPC cohort. The CpG methylation sites were clustered into 3 modules, CpG# -72 to -42; CpG# -40 to -35 and -31 to -19; CpG# -34 to -32 and -18 to 65. (D) Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on all the CpG methylation sites in the Met CRPC cohort. The methylation sites were clustered into 2 modules, CpG# -72 to -35, -31; CpG# -34 to -32 and -30 to 65. (E) The average methylation level of all tested CpG methylation sites in CRPC and benign prostatic tissues in the Local CRPC cohort. (F) The average methylation level of all tested CpG methylation sites in CRPC and benign prostatic tissues in the Met CRPC cohort. (G) The average methylation level of module 1: CpG# -72 to -40 in CRPC and benign prostatic tissues in the Local CRPC cohort. (H) The average methylation level of module 1: CpG# -72 to -40 in CRPC and benign prostatic tissues in the Met CRPC cohort. (I) The average methylation level of module 2: CpG# -39 to 65 in CRPC and benign prostatic tissues in the Local CRPC cohort. (J) The average methylation level of module 2: CpG# -39 to 65 in CRPC and benign prostatic tissues in the Met CRPC cohort.</p

Supplementary Table 1 from Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide

Distribution patterns of PD-L1(+) tumor cells in hormone-naïve PCa.</p

Patients and Clinical Characteristics.

<p>Patients and Clinical Characteristics.</p